Natera (NASDAQ:NTRA) CEO Sells $9,089,637.72 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.
• On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32.
• On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $1,147,822.99.

Natera Stock Performance

Shares of Natera stock traded down $6.79 during trading hours on Friday, hitting $215.31. The company’s stock had a trading volume of 848,951 shares, compared to its average volume of 1,640,936. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The firm has a fifty day moving average of $204.19 and a 200-day moving average of $216.06. The stock has a market cap of $30.83 billion, a price-to-earnings ratio of -132.09 and a beta of 1.56.

Hedge Funds Weigh In On Natera

Several hedge funds have recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC grew its position in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC lifted its stake in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Natera during the second quarter worth about $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera in the second quarter worth about $558,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Robert W. Baird set a $265.00 price target on Natera in a report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Evercore reissued an “outperform” rating and issued a $270.00 target price on shares of Natera in a research report on Friday, May 8th. Piper Sandler reaffirmed an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. increased their price objective on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.12.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.